<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04022109</url>
  </required_header>
  <id_info>
    <org_study_id>824986</org_study_id>
    <secondary_id>lzp-2018/2-0228</secondary_id>
    <secondary_id>KC-L-2017/5</secondary_id>
    <nct_id>NCT04022109</nct_id>
  </id_info>
  <brief_title>Screening of Gastric Cancer Via Breath Volatile Organic Compounds by Hybrid Sensing Approach</brief_title>
  <acronym>VOGAS</acronym>
  <official_title>Screening of Gastric Cancer Via Breath Volatile Organic Compounds by Hybrid Sensing Approach</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Latvia</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Technion, Israel Institute of Technology</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Ulm</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>UPPSALA UNIVERSITET</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>JLM Innovation GmbH</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Universitaet Innsbruck</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Hospital Universitario San Ignacio</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Universidad de Pamplona</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Pontificia Universidad Catolica de Chile</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>AC Camargo Cancer Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Cancer Institute, Ukraine</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>VTT Technical Research Centre of Finland</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Latvia</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study is aimed to determine the potential of volatile marker testing for gastric cancer
      screening.

      The study will be addressing the role of confounding factors, including lifestyle factors,
      diet, smoking as well as addressing the potential role of microbiota in the composition of
      exhaled volatile markers.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients with established disease (gastric cancer, precancerous lesions) as well as patients
      investigated for the lesions and having been documented lack of the lesions will be enrolled
      to the study at clinical sites in Europe (Latvia, Ukraine) and Latin America (Colombia,
      Chile, Brazil). In addition, group of persons from general population at average risk for
      developing the target disease and individuals being referred for upper endoscopy according to
      clinical indications will be also enrolled.

      Testing of volatile markers will be conducted by one of two methods: 1) gas chromatography
      coupled to mass spectroscopy (GS-MS) and 2) sensor technology. Various sensors will be used
      and evaluated for the purpose.

      The potential sources of volatile organic compounds (VOCs) in the breath will be addressed by
      studying VOC emission by using headspace analysis from cancer tissue, gastric contents,
      cancer cell cultures and H.pylori.

      The potential role of gastric and faecal microbiota in the origin of VOCs in the breath will
      be addressed. Metabolome in the circulation will also get correlated to VOCs in the breath
      and with microbiome.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">August 2019</start_date>
  <completion_date type="Anticipated">December 2026</completion_date>
  <primary_completion_date type="Anticipated">December 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Characteristic VOC pattern identification for gastric cancer detection</measure>
    <time_frame>2 years following initiation of patient recruitment</time_frame>
    <description>The characteristic VOC pattern based on sensor analysis and its performance indicators will be detected</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Specific chemistry identification in the exhaled breath</measure>
    <time_frame>2 years following initiation of patient recruitment</time_frame>
    <description>Identification of specific chemistries (GC-MS analysis) originating from gastric cancer</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Characteristic VOC pattern identification for gastric precancerous lesion detection</measure>
    <time_frame>2.5 years following initiation of patient recruitment</time_frame>
    <description>The characteristic VOC pattern based on sensor analysis and its performance indicators will be detected</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Identification of the best-performing sensors</measure>
    <time_frame>3 years following initiation of patient recruitment</time_frame>
    <description>Comparative analysis between the performance of different sensor performance in target disease identification</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Gut microbiota analysis in relation to breath VOCs</measure>
    <time_frame>3 years following initiation of patient recruitment</time_frame>
    <description>Analysis of the role of gastric and faecal microbiota in the origin of VOCs in the exhaled breath</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Confounding factor analysis</measure>
    <time_frame>3 years following initiation of patient recruitment</time_frame>
    <description>The role of confounding factors will be addressed to address their role in VOC emission</description>
  </other_outcome>
  <number_of_groups>5</number_of_groups>
  <enrollment type="Anticipated">5000</enrollment>
  <condition>Gastric Cancer</condition>
  <condition>Atrophic Gastritis</condition>
  <condition>Gastric Dysplasia</condition>
  <condition>H.Pylori Infection</condition>
  <arm_group>
    <arm_group_label>Gastric cancer patients undergoing surgery</arm_group_label>
    <description>Patients with histologically confirmed gastric cancer (adenocarcinoma) planned for surgical management</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Gastric cancer patients</arm_group_label>
    <description>Patients with histologically confirmed gastric cancer (adenocarcinoma)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control group patients without gastric cancer</arm_group_label>
    <description>Patients without gastric malignant disease according to data obtained in upper endoscopy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Average risk population</arm_group_label>
    <description>Average risk population of both genders aged 40-64 at the time of inclusion lacking alarm symptoms for gastrointestinal cancer</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Patients with dyspeptic symptoms</arm_group_label>
    <description>Patients with dyspeptic symptoms or other complains being referred for upper endoscopy (Chile)</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Breath sampling for VOC detection</intervention_name>
    <description>Breath sampling will be performed by using a special sensor device and or GC-MS analysis (by collecting breath samples in adsorbent tubes). Pepsinogen testing will be used in a subgroup to identify serological increased risk for atrophy</description>
    <arm_group_label>Average risk population</arm_group_label>
    <arm_group_label>Control group patients without gastric cancer</arm_group_label>
    <arm_group_label>Gastric cancer patients</arm_group_label>
    <arm_group_label>Gastric cancer patients undergoing surgery</arm_group_label>
    <arm_group_label>Patients with dyspeptic symptoms</arm_group_label>
    <other_name>Serum, plasma sampling for group description and stratification</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Surgery material collection for VOC headspace analysis</intervention_name>
    <description>Only for gastric cancer patients undergoing surgery (Group 1)</description>
    <arm_group_label>Gastric cancer patients undergoing surgery</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Upper endoscopy</intervention_name>
    <description>Routine endoscopic evaluation with a standard biopsy work-up according to updated Sydney system. Additional gastric contents for GC-MS and microbiota analysis in a subgroup. Endoscopy will be used only according to the clinical indications (in Group 4 - according to the results of pepsinogen tests)</description>
    <arm_group_label>Average risk population</arm_group_label>
    <arm_group_label>Control group patients without gastric cancer</arm_group_label>
    <arm_group_label>Gastric cancer patients</arm_group_label>
    <arm_group_label>Gastric cancer patients undergoing surgery</arm_group_label>
    <arm_group_label>Patients with dyspeptic symptoms</arm_group_label>
    <other_name>Histological and microbial evaluation of biopsy samples and gastric content</other_name>
  </intervention>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Microbiota testing</intervention_name>
    <description>Faecal and gastric contents and biopsy samples for microbiota testing</description>
    <arm_group_label>Average risk population</arm_group_label>
    <arm_group_label>Control group patients without gastric cancer</arm_group_label>
    <arm_group_label>Gastric cancer patients</arm_group_label>
    <arm_group_label>Gastric cancer patients undergoing surgery</arm_group_label>
    <arm_group_label>Patients with dyspeptic symptoms</arm_group_label>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Exhaled air samples being stored in specific adsorbent media Plasma/serum samples for group
      stratification Biopsy samples from stomach for histological assessment and microbiota
      analysis Gastric content samples for GC-MS and microbiota analysis Faecal samples for occult
      blood testing and microbiota analysis
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Cancer patient population will be recruited in the major specialized cancer centres in
        Europe (Latvia, Ukraine) and Latin America (Colombia, Chile, Brazil) Control group patients
        will be recruited in the major specialized endoscopy centres in Europe (Latvia, Ukraine)
        and Latin America (Colombia, Chile, Brazil), most frequently - the same institutions as for
        cancer patient recruitment General population group (40-64 years) will be predominantly
        recruited in Latvia from the general population Symptomatic patient validation cohort
        (Group 5) will be predominantly recruited in Chile from the endoscopy referrals
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with verified gastric cancer (Group 1 &amp; 2)

          -  Patients undergoing or having undergone upper endoscopy according to clinical
             indications (Group 3 &amp; 5)

          -  Average-risk population group aged 40-64 at inclusion without alarm symptoms (Group 4)

          -  Motivation to participate in the study

          -  Physical status allowing volatile marker sampling and other procedures within the
             protocol

          -  Signed consent

        Exclusion Criteria:

          -  Known other active cancer

          -  Ventilation problems, airway obstruction

          -  Unwillingness or inability to co-operate
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
  </eligibility>
  <overall_official>
    <last_name>Hossam Haick, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>TECHNION, Israel Institute for Technology</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Marcis Leja, MD, PhD</last_name>
    <phone>+37129497500</phone>
    <email>marcis.leja@lu.lv</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Daiga Santare, MD, PhD</last_name>
    <phone>+37129221107</phone>
    <email>daiga.santare@lu.lv</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>A.C.Camargo Cancer Center</name>
      <address>
        <city>São Paulo</city>
        <country>Brazil</country>
      </address>
    </facility>
    <contact>
      <last_name>Emmanuel Dias Neto, MD, PhD</last_name>
      <email>emmanuel@accamargo.org.br</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Pontificia Universidad Catolica de Chile</name>
      <address>
        <city>Santiago</city>
        <country>Chile</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centro Javeriano de Oncología, San Ignacio University Hospital</name>
      <address>
        <city>Bogotá</city>
        <country>Colombia</country>
      </address>
    </facility>
    <contact>
      <last_name>Raul Murillo, MD, PhD</last_name>
      <email>raulhmurillo@yahoo.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Institute of Clinical and Preventive Medicine, University of Latvia</name>
      <address>
        <city>Riga</city>
        <zip>LV1050</zip>
        <country>Latvia</country>
      </address>
    </facility>
    <contact>
      <last_name>Marcis Leja, MD, PhD</last_name>
      <phone>+37129497500</phone>
      <email>marcis.leja@lu.lv</email>
    </contact>
    <contact_backup>
      <last_name>Daiga Santare, MD, PhD</last_name>
      <phone>+37129221107</phone>
      <email>daiga.santare@lu.lv</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>National Cancer Institute of Ukraine</name>
      <address>
        <city>Kiev</city>
        <country>Ukraine</country>
      </address>
    </facility>
    <contact>
      <last_name>Andrii Lukashenko, MD, PhD</last_name>
      <email>mail.onco@gmail.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Brazil</country>
    <country>Chile</country>
    <country>Colombia</country>
    <country>Latvia</country>
    <country>Ukraine</country>
  </location_countries>
  <link>
    <url>https://www.vogas.eu/</url>
    <description>Horizon 2020 project VOGAS web-page</description>
  </link>
  <reference>
    <citation>Mochalski P, Leja M, Gasenko E, Skapars R, Santare D, Sivins A, Aronsson DE, Ager C, Jaeschke C, Shani G, Mitrovics J, Mayhew CA, Haick H. Ex vivo emission of volatile organic compounds from gastric cancer and non-cancerous tissue. J Breath Res. 2018 Jul 30;12(4):046005. doi: 10.1088/1752-7163/aacbfb.</citation>
    <PMID>29893713</PMID>
  </reference>
  <reference>
    <citation>Krilaviciute A, Stock C, Leja M, Brenner H. Potential of non-invasive breath tests for preselecting individuals for invasive gastric cancer screening endoscopy. J Breath Res. 2018 Apr 4;12(3):036009. doi: 10.1088/1752-7163/aab5be.</citation>
    <PMID>29528036</PMID>
  </reference>
  <reference>
    <citation>Amal H, Leja M, Funka K, Skapars R, Sivins A, Ancans G, Liepniece-Karele I, Kikuste I, Lasina I, Haick H. Detection of precancerous gastric lesions and gastric cancer through exhaled breath. Gut. 2016 Mar;65(3):400-7. doi: 10.1136/gutjnl-2014-308536. Epub 2015 Apr 13.</citation>
    <PMID>25869737</PMID>
  </reference>
  <reference>
    <citation>Krilaviciute A, Heiss JA, Leja M, Kupcinskas J, Haick H, Brenner H. Detection of cancer through exhaled breath: a systematic review. Oncotarget. 2015 Nov 17;6(36):38643-57. doi: 10.18632/oncotarget.5938. Review.</citation>
    <PMID>26440312</PMID>
  </reference>
  <reference>
    <citation>Leja M, You W, Camargo MC, Saito H. Implementation of gastric cancer screening - the global experience. Best Pract Res Clin Gastroenterol. 2014 Dec;28(6):1093-106. doi: 10.1016/j.bpg.2014.09.005. Epub 2014 Sep 28. Review.</citation>
    <PMID>25439074</PMID>
  </reference>
  <reference>
    <citation>Leja M, Amal H, Lasina I, Skapars R, Sivins A, Ancans G, Tolmanis I, Vanags A, Kupcinskas J, Ramonaite R, Khatib S, Bdarneh S, Natour R, Ashkar A, Haick H. Analysis of the effects of microbiome-related confounding factors on the reproducibility of the volatolomic test. J Breath Res. 2016 Jun 24;10(3):037101. doi: 10.1088/1752-7155/10/3/037101.</citation>
    <PMID>27341527</PMID>
  </reference>
  <verification_date>July 2019</verification_date>
  <study_first_submitted>July 12, 2019</study_first_submitted>
  <study_first_submitted_qc>July 12, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">July 16, 2019</study_first_posted>
  <last_update_submitted>July 17, 2019</last_update_submitted>
  <last_update_submitted_qc>July 17, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">July 18, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Latvia</investigator_affiliation>
    <investigator_full_name>Marcis Leja</investigator_full_name>
    <investigator_title>Director, Institute of Clinical and Preventive Medicine</investigator_title>
  </responsible_party>
  <keyword>Volatile organic compounds</keyword>
  <keyword>Breath testing</keyword>
  <keyword>Gastric cancer</keyword>
  <keyword>Atrophic gastritis</keyword>
  <keyword>Precancerous lesions</keyword>
  <keyword>Screening</keyword>
  <keyword>Nanosensor technology</keyword>
  <keyword>GC-MS</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Stomach Neoplasms</mesh_term>
    <mesh_term>Gastritis</mesh_term>
    <mesh_term>Gastritis, Atrophic</mesh_term>
    <mesh_term>Atrophy</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

